Vir Biotechnology Inc. (NASDAQ: VIR) reported Q3 EPS of $1.30, $1.72 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $374.6 million versus the consensus estimate of $146.35 million.

For earnings history and earnings-related data on Vir Biotechnology Inc. (VIR) click here.